Barrett's Esophagus Clinical Trials

A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 349 clinical trials
Intratumoral Gene Mediated Cytotoxic Immunotherapy (GMCI) For Resectable Non-Small Cell Lung Cancer

At least 6 patients will be enrolled at the maximum tolerated dose (MTD) or the highest dose level if a MTD is not reached. The drug will be delivered during scheduled staging procedure via a transbronchial or surgical approach.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Pulmonary Vascular Complications of Liver Disease 3

Patients in need of a liver transplant evaluation or have portopulmonary hypertension or are suspected of having portopulmonary hypertension will be recruited to participate in a Study Day Visit where blood/urine will be collected and diagnostic tests will be performed. Most of these tests are considered standard of care.

  • 0 views
  • 19 Feb, 2024
  • 1 location
An Open-Label Phase 2 Proof or Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471

The study will enroll patients with biopsy-confirmed C3G or IC-MPGN who meet eligibility criteria for this study. There will be a multi-step screening process. At the initial screening visit, all screening eligibility assessments, except the renal biopsy, will be performed.

  • 0 views
  • 19 Feb, 2024
  • 1 location
An Open-label Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects with Pulmonary Arterial Hypertension Currently Using Tyvaso

A minimum of 45 patients from 15 sites in the US will be enrolled in the study.

  • 0 views
  • 19 Feb, 2024
  • 1 location
PILOT STUDY EVALUATING THE UPTAKE OF [18F]F-GLN BY PET/CT IN BREAST CANCER

Patients will be approached about study participation regardless of race or ethnic background. We anticipate enrolling up to 30 evaluable participants.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase II Study of the Anti-GITR Agonist INCAGN01876 and the PD-1 Inhibitor INCMGA00012 in Combination with Stereotactic Radiosurgery in Recurrent Glioblastoma

INCAGN01876 (anti-GITR) 300mg will be administered IV every 2 weeks until disease progression, unacceptable toxicity, or 2 years, whichever occurs first. INCMGA00012 (anti-PD1) 500mg will be administered IV every 4 weeks until disease progression, unacceptable toxicity, or 2 years, whichever occurs first.

  • 0 views
  • 19 Feb, 2024
  • 1 location
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients: A Pilot Trial with Concurrent Controls to Confirm Safety and Assess Preliminary Efficacy

The lymph drainage will continue for up to a maximum of 7 days and will be continued in those patients discharged from ICU back to the ward before that time. The lymph (and time matched blood) will be periodically sampled to detect changes in composition which will be correlated with …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study to Evaluate the Efficacy Safety and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin Hizentra) in Adults with Dermatomyositis (DM)

Screening: about 2 months, 52-week treatment period. Duration of the study will be approximately 3.5 years. A sufficient number of subjects will be screened in order to randomize 126 subjects into the study. Key eligibility criteria: Adults with moderate to severe DM with failure of other therapies.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Psoriatic Arthritis Research Collaborative: Biologic Sub-Study (PARC-B)

The doctor will ask questions about your health, do a physical exam, and get a blood sample. Information from these activities will be entered into a scientific database. Information that could identify you will not be included.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Pilot Study to Evaluate the Effect of CT1812 Treatment on A-beta Oligomer Displacement into CSF in Subjects with Mild to Moderate Alzheimer's Disease

Participants will have CSF and plasma sampling for 3 hours prior to drug administration and then for 24 hours post-drug administration. Up to 18 subjects will be enrolled; interim analyses will be conducted after first 6 and next 6 to assess dosage of CT1812 and to determine if there is …

  • 0 views
  • 19 Feb, 2024
  • 1 location